Agenovir Overview

  • Founded
  • 2014
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Agenovir General Information

Description

Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Primary Office
  • 7000 Shoreline Court
  • Suite 320
  • South San Francisco, CA 94080
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Agenovir Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 09-May-2018 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 17-May-2016 000.00 000.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2016 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Agenovir’s complete valuation and funding history, request access »

Agenovir Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Agenovir’s complete cap table history, request access »

Agenovir Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral re
Therapeutic Devices
South San Francisco, CA
000.00
000000&0 000.00

00000000

i ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
00000000000 0000000
Bothell, WA
00 As of 0000
0000
000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agenovir Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000000 000000 Formerly VC-backed Bothell, WA 00 0000 000000000 0000
You’re viewing 1 of 1 competitors. Get the full list »

Agenovir Executive Team (5)

Name Title Board Seat Contact Info
Dirk Thye MD Chief Executive Officer, President and Board Member
Stephen Quake Ph.D Co-Founder, Board Member & Chairman of the Scientific Advisory Board
Bolyn Hubby Ph.D Chief Scientific Officer
Angela Wu Co-Founder & Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

Agenovir Board Members (4)

Name Representing Role Since
Stephen Quake Ph.D Agenovir Co-Founder, Board Member & Chairman of the Scientific Advisory Board 000 0000
William Smith Agenovir Board Member, Intellectual Property 000 0000
You’re viewing 2 of 4 board members. Get the full list »

Agenovir Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
California Institute for Quantitative Biosciences Accelerator/Incubator 000 0000 000000 0
Celgene Corporation Minority 000 0000 000000 0
Data Collective Venture Capital Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »